依达拉奉治疗急性脑梗死的临床观察

目的观察依达拉奉注射液治疗急性脑梗死（ACI）的疗效。方法采用随机对照试验，选择发病24h内的ACI患者64例，随机分为依达拉奉治疗组（31例）及对照组（33例），治疗前后定期对患者进行神经功能缺损评定，日常生活活动能力（ADL）评定，神经功能缺损评定采用中国卒中量表（CSS），ADL评定采用Barthel指数量表，以治疗第21天CSS和ADL改变作为主要疗效判断标准。结果21d后治疗组、对照组CSS相比差异有显著性（P〈0．05）；两组ADL相比差异有极显著性（P〈0．001），治疗组无明显不良反应。结论依达拉奉能有效改善急性脑梗死的神经功能缺失和日常生活活动能力，无明显不良反应。

Clinical observation of the treatment of acute cerebral infarction with Edaravone

Objective To evaluate efficacy and adverse reactions of Edaravone, a novel hydroxyl-free radical scavenger, on acute cerebral infarction (ACI) . Methods We performed a randomized controlled study on ACI patients. 64 patients, enrolled within 24h of onset, were allocated to Edaravone group(n=31) or control group(n=33) randomly. Before and after treatment, we assessed the neurological deficits and activities of daily living (ADL) using Chinese Stroke Scale(CSS)and Barthel Index respectively. Clinical efficacy was evaluated according to changes of CSS and ADL scores on the 21th day. Results On the 21th day, CSS and ADL were evaluted. There was a significant difference of CSS scores between Edaravone group and the control group (P<0.05). There was a significant difference of ADL scores between Edaravone group and the control group (P<0.001). There was no distinct adverse reaction in Edaravone group. Conclusion Edaravone can improve the neurological function impairment and activities of daily living of acute cerebral infarction patients, without obvious adverse reaction.